HPV Shot: Safety Profile
HPV Shot: Efficacy

HPV Shot Safety Profile

Arana, J. E., Harrington, T., Cano, M., Lewis, P., Mba-Jonas, A., Rongxia, L., … & Shimabukuro, T. T. (2018). Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009–2015. Vaccine, 36(13), 1781-1788.

Block, S. L., Brown, D. R., Chatterjee, A., Gold, M. A., Sings, H. L., Meibohm, A., … & Zhou, H. (2010). Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. The Pediatric infectious disease journal, 29(2), 95-101.

Castellsagué, X. (2008). Natural history and epidemiology of HPV infection and cervical cancer. Gynecologic oncology, 110(3), S4-S7.

Castellsague, X., Munoz, N., Pitisuttithum, P., Ferris, D., Monsonego, J., Ault, K., … & Bryan, J. (2011). End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. British journal of cancer, 105(1), 28.

Feiring, B., Laake, I., Bakken, I. J., Greve-Isdahl, M., Wyller, V. B., Håberg, S. E., … & Trogstad, L. (2017). HPV vaccination and risk of chronic fatigue syndrome/myalgic encephalomyelitis: a nationwide register-based study from Norway. Vaccine, 35(33), 4203-4212.

Garland, S. M., Ault, K. A., Gall, S. A., Paavonen, J., Sings, H. L., Ciprero, K. L., … & Zhou, H. (2009). Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstetrics & Gynecology, 114(6), 1179-1188.

Gee, J., Naleway, A., Shui, I., Baggs, J., Yin, R., Li, R., … & Klein, N. P. (2011). Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine, 29(46), 8279-8284

Green, A. (2018). HPV vaccine to be offered to boys in England. The Lancet, 392(10145), 374.

Harper, D. M., & DeMars, L. R. (2017). HPV vaccines–A review of the first decade. Gynecologic oncology, 146(1), 196-204.

Huh, W. K., Joura, E. A., Giuliano, A. R., Iversen, O. E., de Andrade, R. P., Ault, K. A., … & Mayrand, M. H. (2017). Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. The Lancet, 390(10108), 2143-2159.

Klein, N. P., Hansen, J., Chao, C., Velicer, C., Emery, M., Slezak, J., … & Cheetham, T. C. (2012). Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Archives of pediatrics & adolescent medicine, 166(12), 1140-1148.

Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., … & Jansen, K. U. (2002). A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine, 347(21), 1645-1651.

Macki, M., & Dabaja, A. A. (2016). Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials. Basic and clinical andrology, 26(1), 16.

Miranda, S., Chaignot, C., Collin, C., Dray-Spira, R., Weill, A., & Zureik, M. (2017). Human papillomavirus vaccination and risk of autoimmune diseases: a large cohort study of over 2 million young girls in France. Vaccine, 35(36), 4761-4768.

Muñoz, N., Manalastas Jr, R., Pitisuttithum, P., Tresukosol, D., Monsonego, J., Ault, K., … & Bautista, O. (2009). Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. The Lancet, 373(9679), 1949-1957.

Naud, P. S., Roteli-Martins, C. M., De Carvalho, N. S., Teixeira, J. C., de Borba, P. C., Sanchez, N., … & Descamps, D. (2014). Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Human vaccines & immunotherapeutics, 10(8), 2147-2162.

Ogawa, Y., Takei, H., Ogawa, R., & Mihara, K. (2017). Safety of human papillomavirus vaccines in healthy young women: a meta-analysis of 24 controlled studies. Journal of pharmaceutical health care and sciences, 3(1), 18.

Paavonen, J., Jenkins, D., Bosch, F. X., Naud, P., Salmerón, J., Wheeler, C. M., … & de Carvalho, N. S. (2007). Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. The Lancet, 369(9580), 2161-2170.

Rosmarin, D. H., Pirutinsky, S., Appel, M., Kaplan, T., & Pelcovitz, D. (2018). Childhood sexual abuse, mental health, and religion across the Jewish community. Child abuse & neglect, 81, 21-28.

Siegrist, C. A., Lewis, E. M., Eskola, J., Evans, S. J., & Black, S. B. (2007). Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. The Pediatric infectious disease journal, 26(11), 979-984

Stokley, S., Jeyarajah, J., Yankey, D., Cano, M., Gee, J., Roark, J., … & Markowitz, L. (2014). Human papillomavirus vaccination coverage among adolescents, 2007–2013, and postlicensure vaccine safety monitoring, 2006–2014—United States. MMWR. Morbidity and mortality weekly report, 63(29), 620.

Yehuda, R., Friedman, M., Rosenbaum, T. Y., Labinsky, E., & Schmeidler, J. (2007). History of past sexual abuse in married observant Jewish women. American journal of psychiatry, 164(11), 1700-1706.

Yih, W. K., Greene, S. K., Zichittella, L., Kulldorff, M., Baker, M. A., de Jong, J. L., … & McMahill-Walraven, C. N. (2016). Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females. Vaccine, 34(1), 172-178.

HPV Vaccine Works to Prevent HPV and Cervical Cancers

Arbyn, M., Xu, L., Simoens, C., & Martin‐Hirsch, P. P. (2018). Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database of Systematic Reviews, (5).

Arrossi, S., Paolino, M., Laudi, R., Gago, J., Campanera, A., Marín, O., … & Thouyaret, L. (2019). Programmatic human papillomavirus testing in cervical cancer prevention in the Jujuy Demonstration Project in Argentina: a population-based, before-and-after retrospective cohort study. The Lancet Global Health, 7(6), e772-e783.

Castellsague, X., Munoz, N., Pitisuttithum, P., Ferris, D., Monsonego, J., Ault, K., … & Bryan, J. (2011). End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. British journal of cancer, 105(1), 28.

Schwarz, T. F., Huang, L. M., Lin, T. Y., Wittermann, C., Panzer, F., Valencia, A., … & Descamps, D. (2014). Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10-to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial. The Pediatric infectious disease journal, 33(12), 1255-1261

Schwarz, T. F., Galaj, A., Spaczynski, M., Wysocki, J., Kaufmann, A. M., Poncelet, S., … & Struyf, F. (2017). Ten‐year immune persistence and safety of the HPV‐16/18 AS 04‐adjuvanted vaccine in females vaccinated at 15–55 years of age. Cancer medicine, 6(11), 2723-2731.

Simms, K. T., Steinberg, J., Caruana, M., Smith, M. A., Lew, J. B., Soerjomataram, I., … & Canfell, K. (2019). Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modelling study. The Lancet Oncology, 20(3), 394-407.